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female with multiple myeloma and secondary engraftment
failure after high dose chemotherapy with autologous he-
matopoietic stem cell transplantation (AHSCT) on day +64.
The patient presented with severe pancytopenia and a
bone marrow biopsy and aspirates revealed a hypocellular
marrow without increased plasma cells. An extensive in-
fectious disease work up was negative for bacterial, fungal
or viral source including cytomegalovirus, HHV 6, parovi-
rus, BK virus, and adenovirus. The patient received stem
cell boost on day +98 and failed to engraft. A repeat bone
marrow biopsy performed on day +127 revealed less than
10% cellularity with no signs of hematopoiesis and no
plasma cells. Therefore, the patient met the criteria for
severe aplastic anemia (AA). The patient was initiated on
eltrombopaq after one week treatment of steroid and
cyclosporine with minimal improvement in neutrophil
counts. Although uncommon, the case study examines the
rare occurrence of AA in the post-transplant population.
The case report highlights that secondary engraftment
failure and AA are uncommon complications of AHSCT and
can be life threatening. Careful clinical evaluation and pa-
thology review are necessary to determine the cause of
graft failure in the autologous transplant setting in order to
provide the appropriate medical and supportive care.161
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Purpose: Engraftment syndrome (ES) is a complication of
autologous hematopoietic stem cell transplantation
(HSCT) characterized by non-infectious fever, skin rash,
diarrhea, and inﬂammatory manifestations. Acute renal
dysfunction is a less frequently reported complication of
ES, occurring in up to 26% of patients. No prior investi-
gation has identiﬁed speciﬁc risk factors for developing
acute renal failure in this patient population. The objec-
tive of this study is to determine risk factors associated
with the development of acute renal dysfunction in pa-
tients with ES.
Methods: This study will be submitted to the University of
Texas Health Science Center and Veterans Affairs Institu-
tional Review Board for approval. This retrospective
cohort study will identify all patients receiving autologous
HSCT from January 2011 to December 2013 at a single
institution. Patients with a diagnosis of ES (per the
Maiolino criteria: non-infectious fever plus one of the
following: skin rash, pulmonary inﬁltrates, or diarrhea
which commences 24 hours before, or any time after
appearance of neutrophils) will be identiﬁed. Potential
risk factors that may lead to the development of acute
renal dysfunction during the time of ES will be analyzed.
Data collected will include: baseline demographics, un-
derlying malignancy, comorbid conditions, mobilization
regimen, conditioning regimen, number of CD34 cells
infused, time of engraftment, date of ﬁrst fever, physical
examination, medications, clinical lab values, and length
of hospital admission. Descriptive statistical analyses willbe performed for discrete variables by using Pearson’s chi-
squared test or Fisher’s exact test appropriately. Risk fac-
tors will be analyzed using a backward stepwise logistic
regression model.162
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Background: In 2014, high-dose chemotherapy with autol-
ogous stem cell rescue (autoSCT) was removed from the
NCCN guidelines as a recommended treatment for patients
<60 years old with intermediate-risk (int-risk) AML in ﬁrst
complete remission (CR1). We comprehensively reviewed
the long-term outcomes of all patients with int-risk AML
treated with autoSCT in CR1 at our institution.
Patients and Methods: This is a retrospective, single insti-
tution study of all patients with int-risk AML treated with
autoSCT in CR1 between 1988-2013. Data were collected by
chart review. Publicly available death indices were accessed
to ensure accurate dates of death, with censoring of data on
September 1, 2014. For all analyses, patients with <1 year
follow-up were considered to have relapsed at the date of
last follow-up. Statistical analyses were performed using
STATA SE 9.
Results: We identiﬁed 133 patients with int-risk AML who
underwent autoSCT in CR1. Cytogenetics were diploid in 97
(73%); FLT3mutation status was only assessed routinely after
2008 (21 patients total, 17/21 negative).
Of the 133 patients, 55% were women and 69% were
Caucasian. Median age at autoSCT was 47 years (range 20-
72). Mean CD34+ cell dose infused was 13 x 106/kg (range
2.6-63). Ten percent of patients were treated pre-1993 with
bone marrow stem cells and PO busulfan (BU), 28% between
1993-2003 with peripheral blood stem cells (PBSCs) and PO
BU, 35% between 2003-2007 with PBSCs and IV BU, and 28%
post-2007 with PBSCs and targeted IV BU (all with 60mg/kg
IV etoposide).
With a median follow-up of 4.3 years (range 0.1-17),
median relapse-free survival (RFS) has not been reached; 52%
of patients remain relapse-free. Fourteen (10%) patients
developed therapy-related MDS or AML. In multivariate
analysis, relapse was predicted by non-Caucasian race (HR
2.5, p¼0.001) and by treatment era post-2007 (HR 1.85,
p¼0.025). Median overall survival (OS) for the entire cohort
is 6.6 years (range 0.1-17).
Twenty-six of 54 relapsing patients (48%) subsequently
received an alloSCT, with 16 (62%) proceeding to alloSCT in
CR2 and 7 (27%) with active disease. Twelve (46%) patients
relapsed following alloSCT. Of the 26 alloSCT patients, 9
(35%) died from treatment-related causes and 9 (35%) from
AML relapse. Median follow-up for patients receiving salvage
alloSCT is 3.8 years (range 0.17-7.8) with 8 (31%) patients
known to be alive and in remission. Median RFS after alloSCT
is 2.5 years (range 0.02-4.32).
